Dr Graham talks with ecancer at the ACP immunotherapy workshop about CRS, a side effect associated with recently approved CAR-T cell therapies.
She describes the presentation and pathways activated at the onset of cytokine release syndrome, and relates case details from one patient treated with tociluzumab and steroids.
